Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. News
May 12, 2025 - benzinga.com
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
May 7, 2025 - prnewswire.com
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
Apr 24, 2025 - prnewswire.com
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Apr 9, 2025 - prnewswire.com
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
NeuroSense Therapeutics Ltd. Quantitative Score
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
NeuroSense Therapeutics Ltd. Financials
Table Compare
Compare NRSN metrics with: | |||
|---|---|---|---|
Earnings & Growth | NRSN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NRSN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NRSN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NRSN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
NeuroSense Therapeutics Ltd. Income
NeuroSense Therapeutics Ltd. Balance Sheet
NeuroSense Therapeutics Ltd. Cash Flow
NeuroSense Therapeutics Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
NeuroSense Therapeutics Ltd. Executives
| Name | Role |
|---|---|
| Dr. Ferenc Tracik M.D. | Chief Medical Officer |
| Mr. Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director |
| Mr. Or Eisenberg | Chief Financial Officer |
| Ms. Hagit Binder | Chief Operation Officer |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Ferenc Tracik M.D. | Chief Medical Officer | 1964 | 412K | |
| Mr. Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | Male | 1979 | 366K |
| Mr. Or Eisenberg | Chief Financial Officer | Male | 1981 | 279K |
| Ms. Hagit Binder | Chief Operation Officer | Female | 1978 | 218K |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer | 1979 | 188K |